KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash & Current Investments: 2013-2025

Historic Cash & Current Investments for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $110.9 million.

  • Travere Therapeutics' Cash & Current Investments rose 204.68% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.5 million, marking a year-over-year increase of 80.17%. This contributed to the annual value of $58.5 million for FY2024, which is 0.62% up from last year.
  • Travere Therapeutics' Cash & Current Investments amounted to $110.9 million in Q3 2025, which was up 47.60% from $75.2 million recorded in Q2 2025.
  • Travere Therapeutics' Cash & Current Investments' 5-year high stood at $256.6 million during Q1 2022, with a 5-year trough of $32.3 million in Q2 2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $61.9 million (2025), whereas its average is $77.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 74.76% in 2024, then skyrocketed by 204.68% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Cash & Current Investments stood at $165.8 million in 2021, then crashed by 62.78% to $61.7 million in 2022, then declined by 5.69% to $58.2 million in 2023, then rose by 0.62% to $58.5 million in 2024, then spiked by 204.68% to $110.9 million in 2025.
  • Its Cash & Current Investments stands at $110.9 million for Q3 2025, versus $75.2 million for Q2 2025 and $61.9 million for Q1 2025.